BioCentury
ARTICLE | Product R&D

Syncona’s sister act

How Syncona's family of five gene therapy portfolio companies share recipes

July 27, 2018 12:47 AM UTC
””””

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push the modality beyond rare diseases.

The firm designed its portfolio to find low-hanging fruit in gene therapy’s most accessible target organs, and to address the modality’s two biggest challenges -- manufacturing and delivery...